IMMUCELL CORP /DE/ — Investor Relations & Filings
ImmuCell Corporation is an animal health company that develops, manufactures, and markets scientifically-proven products to improve the health and productivity of dairy and beef cattle. The company focuses on disease prevention as a means to reduce the use of antibiotics. Its flagship product line, First Defense®, is a USDA-accredited, colostrum-derived product providing newborn calves with immediate immunity against the primary viral and bacterial causes of scours. ImmuCell is also developing Re-Tain®, a purified nisin-based intramammary treatment for subclinical mastitis in dairy cows, which is pending regulatory approval. The company's core competency lies in its ability to concentrate, purify, and quantify specific colostrum antibodies on a commercial scale to create cost-effective health solutions for producers.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| CURRENT REPORT | 2025-08-25 | English | |
| QUARTERLY REPORT | 2025-08-14 | English | |
| CURRENT REPORT | 2025-08-14 | English | |
| CURRENT REPORT | 2025-08-12 | English | |
| CURRENT REPORT | 2025-07-09 | English | |
| CURRENT REPORT | 2025-06-25 | English |
Browse filings by year
32 years- 2026 18 filings
- 2025 32 filings
- 2024 40 filings
- 2023 32 filings
- 2022 34 filings
- 2021 28 filings
- 2020 29 filings
- 2019 26 filings
- 2018 35 filings
- 2017 36 filings
- 2016 53 filings
- 2015 26 filings
- 2014 30 filings
- 2013 23 filings
- 2012 16 filings
- 2011 30 filings
- 2010 25 filings
- 2009 31 filings
- 2008 29 filings
- 2007 34 filings
- 2006 19 filings
- 2005 28 filings
- 2004 20 filings
- 2003 27 filings
- 2002 15 filings
- 2001 19 filings
- 2000 7 filings
- 1999 6 filings
- 1998 9 filings
- 1997 6 filings
- 1996 6 filings
- 1995 5 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 9652101 | CURRENT REPORT | 2025-08-25 | English | ||
| 9652102 | QUARTERLY REPORT | 2025-08-14 | English | ||
| 9652103 | CURRENT REPORT | 2025-08-14 | English | ||
| 9652104 | CURRENT REPORT | 2025-08-12 | English | ||
| 9652105 | CURRENT REPORT | 2025-07-09 | English | ||
| 9652106 | CURRENT REPORT | 2025-06-25 | English | ||
| 9652107 | CURRENT REPORT | 2025-06-17 | English | ||
| 9652108 | PRIMARY DOCUMENT | 2025-06-13 | English | ||
| 9652110 | PRIMARY DOCUMENT | 2025-06-12 | English | ||
| 9652109 | QUARTERLY REPORT | 2025-05-14 | English | ||
| 9652111 | CURRENT REPORT | 2025-05-14 | English | ||
| 9652112 | PROXY STATEMENT | 2025-04-24 | English | ||
| 9652113 | PRIMARY DOCUMENT | 2025-04-23 | English | ||
| 9652114 | CURRENT REPORT | 2025-04-08 | English | ||
| 9652118 | PRIMARY DOCUMENT | 2025-04-07 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
IMMUCELL CORP /DE/ via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34519/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34519 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34519 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34519 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34519}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for IMMUCELL CORP /DE/ (id: 34519)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.